Department of Orthopedics and Trauma Surgery, Campus Bio-medico University of Rome, Rome, Italy.
Department of Haematology, Stem Cell Transplantation, Transfusion Medicine and Cellular Therapy, Campus Bio-Medico University Hospital, Rome, Italy.
J Biol Regul Homeost Agents. 2016 Oct-Dec;30(4 Suppl 1):41-49.
Cartilage lesions are the most common cause of chronic knee pain. Micro-fracturing is reliable, effective, easy to perform and inexpensive. We propose a novel approach to cartilage lesions where microfractures are performed contextually to intra-operative or post-operative administration of platelet concentrates. We retrospectively evaluate 48 patients divided in 3 groups. Group 1: 15 patients underwent microfractures and intraoperative administration of PRF (PRF group); group 2: 16 microfractures and postoperative injections of PRP (PRP group); group 3: 17 patients with isolated microfractures (Microfractures group). Clinical scores (IKDC, VAS pain) were administered at 2 and 5 years postoperative and MRI was performed to evaluate the lesions of patients according to the MOCART criteria (2006). Patients treated with platelet concentrates achieved better clinical results compared to patients treated with microfracture only. The PRF group showed better results than the PRP group at 2 years, with loss of significance at 5 years. At MOCART score, PRF group obtained better results earlier than the other two groups.
软骨损伤是慢性膝关节疼痛的最常见原因。微骨折术可靠、有效、易于操作且价格低廉。我们提出了一种治疗软骨损伤的新方法,即在微骨折术中或术后局部给予血小板浓缩物。我们回顾性评估了 48 例患者,分为 3 组。第 1 组:15 例患者接受微骨折术和术中富血小板纤维蛋白(PRF 组);第 2 组:16 例患者接受微骨折术和术后富血小板血浆(PRP 组);第 3 组:17 例患者仅接受微骨折术(微骨折组)。术后 2 年和 5 年分别进行临床评分(IKDC、VAS 疼痛),并根据 MOCART 标准(2006 年)进行 MRI 评估患者的病变。与仅接受微骨折术的患者相比,接受血小板浓缩物治疗的患者获得了更好的临床结果。在 2 年时,PRF 组的结果优于 PRP 组,但在 5 年时失去了意义。在 MOCART 评分方面,PRF 组比其他两组更早获得更好的结果。